You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PIK3CA mutant, Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

HER2-positive Metastatic Breast Cancer Trial in Aurora, Madison (Alpelisib, Tucatinib, Fulvestrant)

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • Aurora, Colorado
  • +2 more
Dec 29, 2022

Breast Cancer, Solid Tumor Trial in Worldwide (Inavolisib, Fulvestrant, Letrozole)

Recruiting
  • Breast Cancer
  • Solid Tumor
  • Boston, Massachusetts
  • +12 more
Jan 10, 2023

HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)

Not yet recruiting
  • HER2-positive Breast Cancer
  • (no location specified)
Mar 23, 2022

Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer Trial in

Recruiting
  • Hormone Receptor Positive Breast Carcinoma
  • +2 more
  • Chicago, Illinois
  • +2 more
Jul 1, 2022

Metastatic Breast Cancer, HER2-negative Breast Cancer Trial in Kansas City (Dapagliflozin 10Mg Tab)

Recruiting
  • Metastatic Breast Cancer
  • HER2-negative Breast Cancer
  • Dapagliflozin 10Mg Tab
  • Kansas City, Missouri
    Saint Luke's Cancer Institute
Oct 14, 2021

Breast Cancer Trial in United States (Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib))

Recruiting
  • Breast Cancer
  • Benralizumab
  • fulvestrant or AIs) and PI3K inhibition (alpelisib)
  • Stanford, California
  • +8 more
Aug 1, 2023

HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

Active, not recruiting
  • HER2-positive Breast Cancer
  • PIK3CA analysis
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023

Patterns Among PIK3CA Mutation in Advanced Breast Cancer

Completed
  • Breast Cancer
    • East Hanover, New Jersey
      Novartis
    Aug 1, 2023

    Breast Tumors Trial in China (Alpelisib, Fulvestrant, Placebo)

    Recruiting
    • Breast Neoplasms
    • Hefei, Anhui, China
    • +31 more
    Dec 19, 2022

    Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (MEN1611, Eribulin)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • (no location specified)
    Apr 12, 2023

    Advanced Breast Cancer Trial (CYH33, Fulvestrant, Letrozole)

    Not yet recruiting
    • Advanced Breast Cancer
    • (no location specified)
    Apr 19, 2021

    PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer Trial (RLY-5836, Fulvestrant, Palbociclib)

    Not yet recruiting
    • PIK3CA Mutation
    • +7 more
    • (no location specified)
    Mar 7, 2023

    Breast Cancer Trial (Inavolisib, Fulvestrant, Alpelisib)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jan 30, 2023

    Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)

    Recruiting
    • Advanced Breast Cancer
    • Thalassery, Kerala, India
      Novartis Investigative Site
    Nov 21, 2022

    Metastatic Breast Cancer Trial (Inavolisib, Phesgo, Placebo)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Jun 7, 2023

    A NIS of Alpelisib in Combination With Fulvestrant in

    Not yet recruiting
    • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
    • Alpelisib
    • Fulvestrant
    • (no location specified)
    Aug 9, 2022

    Breast Cancer Trial in Worldwide (Alpelisib, Fulvestrant, Letrozole)

    Active, not recruiting
    • Breast Cancer
    • Gilbert, Arizona
    • +93 more
    Nov 10, 2022

    Advanced Breast Cancer Trial in Orebro (Alpelisib, fulvestrant)

    Terminated
    • Advanced Breast Cancer
    • Orebro, Sweden
    • +1 more
    Nov 21, 2022

    Colorectal Cancer, Colon Cancer, Rectal Cancer Trial in Cleveland (CB-839, Capecitabine)

    Active, not recruiting
    • Colorectal Cancer
    • +3 more
    • Cleveland, Ohio
    • +1 more
    Jan 14, 2022

    Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

    Recruiting
    • Metastatic Breast Cancer
    • Badalona, Barcelona, Spain
    • +9 more
    Oct 24, 2022

    Tolerability Outcomes of Alpelisib in Real-world

    Recruiting
    • Breast Cancer
    • alpelisib plus fulvestrant
    • Mumbai, Maharashtra, India
    • +3 more
    Jun 8, 2022

    Advanced or Metastatic Breast Cancer Trial in Paris (Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of

    Not yet recruiting
    • Advanced or Metastatic Breast Cancer
    • Milademetan
    • Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
    • Paris, France
      Institut Curie
    Jun 27, 2023

    Breast Cancer Trial in Shanghai (HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2))

    Recruiting
    • Breast Cancer
    • HS-10352 combined with fulvestrant (Stage 1)
    • HS-10352 combined with fulvestrant (Stage 2)
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Aug 15, 2022

    Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

    Recruiting
    • Endometrial Cancer
    • Ovarian Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 27, 2022